Clinical significance of osteoprotegerin expression in human colorectal cancer

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2444-2450

  Tsukamoto, Shunsuke ^a   Ishikawa, Toshiaki ^a   Iida, Satoru ^a   Ishiguro, Megumi ^a   Mogushi, Kaoru ^a   Mizushima, Hiroshi ^a   Uetake, Hiroyuki ^a   Tanaka, Hiroshi ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OPG GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPROTEGERIN; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79954608597     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2884     Document Type: Article

References (39)

1. Ricchi P, Zarrilli R, Di Palma A, Acquaviva AM. Nonsteroidal antiinflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003;88:803-7. (Pubitemid 36520863)
2. Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 2007;141:67-75. (Pubitemid 44918081)
3. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005;365:153-65. (Pubitemid 40091806)
4. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19. (Pubitemid 41103700)
5. Shih W, Chetty R, Tsao MS. Expression profiling by microarrays in colorectal cancer (Review). Oncol Rep 2005;13:517-24.
6. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001;61:6474-9. (Pubitemid 32783254)
7. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-71. (Pubitemid 41079793)
8. Yang SY, Sales KM, Fuller B, Seifalian AM, Winslet MC. Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 2009;15:225-33.
9. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7. (Pubitemid 28319153)
10. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-9. (Pubitemid 34461260)
11. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
12. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008;95:611-9.
13. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001;57:611-6.
14. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004;59:304-10. (Pubitemid 38509763)
15. Ito R, Nakayama H, Yoshida K, Kuraoka K, Motoshita J, Oda N, et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 2003;443:146-51. (Pubitemid 37056138)
16. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002;8:2306-10. (Pubitemid 34753605)
17. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci 2006;110:279-91. (Pubitemid 43348393)
18. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004;15:457-75. (Pubitemid 39550455)
19. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009;66:841-51.
20. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19. (Pubitemid 27199902)
21. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82. (Pubitemid 26091143)
22. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90. (Pubitemid 26175834)
23. Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival? Breast Cancer Res Treat 2005;92:207-15. (Pubitemid 41279631)
24. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62:1619-23. (Pubitemid 34408480)
25. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6. (Pubitemid 36278418)
26. Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, et al. Osteoprotegerin (OPG)-a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 2006;118:1901-8.
27. McGonigle JS, Giachelli CM, Scatena M. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 2009;12:35-46.
28. De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008;14:4713-8.
29. Pettersen I, Bakkelund W, Smedsrod B, Sveinbjornsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res 2005;25:3809-16. (Pubitemid 41665149)
30. + cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009;10:877-84.
31. Zlobec I, Lugli A, Baker K, Roth S, Minoo P, Hayashi S, et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 2007;212:260-8. (Pubitemid 47010060)
32. Johnstone EC, Kerr DJ. What is the role and impact of molecular markers on treatment decisions in the adjuvant setting of colorectal cancer? Ann Oncol 2008;19 Suppl 7: vii184-6.
33. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. (Pubitemid 38702845)
34. Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109:1082-9. (Pubitemid 46435386)
35. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134:1296-310.
36. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
37. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG, et al. The clinical trail of TRAIL. Eur J Cancer 2006;42:2233-40. (Pubitemid 44307615)
38. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAILR1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3450-5.
39. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37. (Pubitemid 40315182)